The relative prevalence of the Omicron variant within SARS-CoV-2 infected cohorts in different countries: A systematic review.
Hum Vaccin Immunother
; 19(1): 2212568, 2023 12 31.
Artigo
em Inglês
| MEDLINE | ID: covidwho-20242458
ABSTRACT
The Omicron variant of SARS-CoV-2 was detected in October 2021 and exhibited high transmissibility, immune evasion, and reduced severity when compared to the earlier variants. The lesser vaccine effectiveness against Omicron and its reduced severity created vaccination hesitancy among the public. This review compiled data reporting the relative prevalence of Omicron as compared to the early variants to give an insight into the existing variants, which may shape the decisions regarding the targets of the newly developed vaccines. Complied data revealed more than 90% prevalence within the infected cohorts in some countries. The BA.1 subvariant predominated over the BA.2 during the early stages of the Omicron wave. Moreover, BA.4/BA.5 subvariants were detected in South Africa, USA and Italy between October 2021 and April 2022. It is therefore important to develop vaccines that protect against Omicron as well as the early variants, which are known to cause more severe complications.
Palavras-chave
Texto completo:
Disponível
Coleções:
Bases de dados internacionais
Base de dados:
MEDLINE
Assunto principal:
COVID-19
Tipo de estudo:
Estudo de coorte
/
Estudo observacional
/
Estudo prognóstico
/
Revisões
/
Revisão sistemática/Meta-análise
Tópicos:
Vacinas
/
Variantes
Limite:
Humanos
País/Região como assunto:
Europa
Idioma:
Inglês
Revista:
Hum Vaccin Immunother
Ano de publicação:
2023
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS